ClinicalTrials.gg
CompletedNCT00158834Updated Oct 13, 2008

Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications

A Phase 3 interventional study of Salmeterol/Fluticasone propionate combination product and Fluticasone propionate in Asthma, sponsored by GlaxoSmithKline. Completed at 16 sites in Netherlands. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2008-10-13.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
6 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
62nd of 146
200 · median 100
Started
1999
with 1 other
Phase 3
35 of 147
none open now
Registered
5th of 147
by date
Lead sponsor
69 of 147
GlaxoSmithKline

Among the 147 studies testing fluticasone in Asthma, this one is the 62nd largest by enrollment of the 146 interventional ones that give a count, is one of 2 that started in 1999, is one of 35 in phase 3, and was the 5th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 6 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

This study was designed to evaluate if, in children with asthma, a stepwise treatment (five levels varying from once daily fluticasone propionate 100mcg until twice daily a fixed combination of salmeterol and fluticasone propionate 50/500 mcg) based on symptom scores alone results in a sub-optimal treatment when compared to treatment based on cumulative symptom scores and bronchial hyperresponsiveness (PD20 methacholine).

03

Conditions studied

  • Asthma

Keywords

  • Children
  • Asthma
  • bronchial hyperresponsiveness
  • symptoms
04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with a documented history of asthma.
  • Using inhaled from 100 mcg up to 500 mcg twice daily for at least 1 month before study start.
  • Must be able to perform reproducible lung function tests.
  • Must have a positive RAST or skin prick test.
  • During the treatment period, the patient has to be hyperreactive (defined as PD20 methacholine \< 150 mcg) and/or have a cumulative symptom score of 14 based on the daily record card filled in during the last 2 weeks of the run-in period.

Exclusion criteria

Exclusion criteria:

  • History of an acute upper or lower respiratory tract infection, middle ear, or sinus infection 4 weeks prior to visit 1.
  • Admitted to hospital due to a respiratory disease 4 weeks prior to visit 1.
  • Received oral within 4 weeks prior to visit 1.
  • Existence of any disorder that affects growth.
  • Clinical or laboratory evidence of a serious systemic disease, or suspected to corticosteroids, lactose or short/long acting B2-agonists.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
200 participants

Interventions

  • DrugSalmeterol/Fluticasone propionate combination product
  • Also known as: Salmeterol/Fluticasone propionate combination product

06

What researchers measure

Primary outcomes

  1. Asthma symptom free days during the last 12 weeks of the treatment period.

Secondary outcomes

  1. Bronchial hyperresponsiveness, determined by PD20 methacholine at the end of the study.

07

Study locations

16 sites
  • GSK Investigational Site
    Alkmaar, 1815 JD, Netherlands
  • GSK Investigational Site
    Almere, 1315 RA, Netherlands
  • GSK Investigational Site
    Amsterdam, 1081 HV, Netherlands
  • GSK Investigational Site
    Amsterdam, 1105 AZ, Netherlands
  • GSK Investigational Site
    Breda, 4818 CK, Netherlands
  • GSK Investigational Site
    Den Haag, 2566 MJ, Netherlands
  • GSK Investigational Site
    Eindhoven, 5623 EJ, Netherlands
  • GSK Investigational Site
    Groningen, 9713 GZ, Netherlands
  • GSK Investigational Site
    Hilversum, 1213 VX, Netherlands
  • GSK Investigational Site
    Leiden, 2333 ZA, Netherlands
  • GSK Investigational Site
    Maastricht, 6229 HX, Netherlands
  • GSK Investigational Site
    Rotterdam, 3015 GD, Netherlands
  • GSK Investigational Site
    Sittard, 6131 BK, Netherlands
  • GSK Investigational Site
    Utrecht, 3584 EA, Netherlands
  • GSK Investigational Site
    Veldhoven, 5504 DB, Netherlands
  • GSK Investigational Site
    Zwolle, 8011 JW, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 13, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00158834
Lead sponsor
GlaxoSmithKline
First posted
Sep 12, 2005
Start date
Nov 1999
Last update
Oct 13, 2008

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion